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INTRODUCTION
The emergence of multidrug-resistant enterococci, especially vancomycin-resistant enterococci (VRE), and its spread has facilitated the occurrence of several hospital outbreaks worldwide. The prevalence in Asian countries is not so high, probably due to recent emergence of this resistance in this continent and only a handful of studies to document. [1] In India, the prevalence of VRE has been reported as' 8%, 5.5% and 23% in New Delhi, Chandigarh, and Mumbai, respectively, all of vanB phenotype. [2] We report a case of neonatal septicemia caused by VRE of vanA genotype, the likely source of infection being the neonate's colonized gut.
CASE REPORT
A less than 1-day-old male, preterm, very low birth weight neonate was admitted to the Neonatal Intensive Care Unit (NICU) with body weight of 1065 g, an Apgar score of 2/10, and features of sepsis. The neonate was delivered from a multigravida mother by lower segment cesarean section with bad obstetric history and history of per vaginal leakage with cord prolapse and oligohydramnios. She had received treatment with ceftriaxone (500 mg intravenous (IV) twice daily) for 5 days. The neonate had received bag and tube ventilation for 2 min following birth using 100% oxygen and had been on bubble continuous positive airway pressure since the 1 st day of life. He has also received phototherapy. His blood was sent for culture but failed to grow any organism initially. He was put on empirical therapy with amikacin (15 mg IV once daily) and piperacillin-tazobactam (50 mg IV twice daily) followed by vancomycin (10 mg IV twice daily) but without any improvement. His initial blood cultures did not show the presence of any organism. On the 10 th day, his blood culture grew Enterococcus faecalis identified by extensive biochemical tests. [3] The isolate was sensitive to linezolid and resistant to ampicillin, high-strength gentamicin, and grew on vancomycin screen agar, with vancomycin minimum inhibitory concentration >256 μg/ml detected both by broth microdilution and E-test method [ Figure 1 ]. The isolate harbored vanA gene as detected by polymerase chain reaction (PCR) [ Figure 2 ]. [4] A preliminary report was immediately dispatched, and surveillance cultures were done to trace the source of VRE. Samples were collected from different surfaces of the neonate such as heel pad, umbilical cord/stump, wrist, oral and nasal mucosa, webs of the fingers, intravenous and urinary catheter, oxygen mask tube, feeding tube, and also from the close environment such as bed and beddings, common door handle of the NICU, wash basin and hand wash, personal belongings such as stethoscope and mobile phones of attending doctors and nurses, and hands of all associated health-care workers. Stool samples both of the neonate and mother were collected and processed. Interestingly, VRE was isolated from unenriched stool of the neonate with comparable susceptibility pattern and genotype profile as that of the blood isolate. Typing the isolates by enterobacterial repetitive intergenic consensus PCR [5] showed that both the isolates from blood and stool were clonally related. The neonate was treated with linezolid (12 mg IV twice daily) and showed improvement and weight gain with an Apgar score of 8/10 on discharge after 19 days of hospital stay.
DISCUSSION
The case report is important in this perspective that we were able to trace the likely source of infection in the septicemic neonate. Most of the recent case reports from India have not been able to trace the source of VRE or detect the genotype. [6, 7] Consequently, the importance of VRE surveillance in stool, especially in ICU and NICU, as an integral part of infection control monitoring has been undermined.
The predominance of vanA gene in East Asian region has already been documented in studies from Japan, Korea, and China. [8] The high rate of transmission of vanA gene to other isolates itself is a potential threat in the hospital environment. We have also reported high vanA genotype VRE carriage rate in stool in association with antibiotic usage in the adult ICU of our tertiary care hospital. [9] However, isolation of VRE in neonate stool with septicemia deserves a special mention due to additional challenges put forward in the management and care of this vulnerable group of patients.
Due to excessive usage of antibiotics other than glycopeptides in nosocomial settings, hospital staff and patients who have survived with prolonged hospital stay like in our case serve as potent VRE reservoirs. Unlike ours, in developed countries, where surveillance culturing systems are taken seriously, patients who are colonized with VRE are routinely identified and the choice of which empiric antibiotic to administer for a presumed nosocomial infection is usually decided by the colonization status of the patients. [10] In patients known to be colonized with VRE, broad-spectrum agents that lack a significant activity against anaerobes would be preferred, on the assumption that potent anaerobic activity would not be required for treating the infection. If the patient is not colonized with VRE, administration of a potent antienterococcal broad-spectrum agent such as piperacillin-tazobactam may be preferred. In this manner, both the establishment of new colonization and the level of colonization of those already colonized could be minimized. [10] Due to lack of any such guideline for the management of VRE-colonized patients in India, we were not able to intervene with the colonization status of the neonate.
Most infections and colonizations with VRE are due to patient's endogenous flora that can spread directly from the patient or indirectly through contaminated surfaces, shared equipment, or hands of health-care workers. [11] In this case, due to strict infection control measures, VRE was not found in the environment of NICU. Therefore, we concluded that translocation of gut flora colonized with VRE might have been responsible for VRE sepsis in the neonate.
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